Chiesi is an international, research-oriented biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and speciality care.
Chiesi invests continuously in research and development to create new therapeutic and technological solutions that enhance patient health and benefit the healthcare community across the respiratory health, rare diseases, and speciality care landscape.
This year, Chiesi will open a Biotech Center of Excellence in Parma, Italy, to produce active ingredients such as monoclonal antibodies. The first products from this new facility are expected to reach the global market by 2025.
With 31 affiliates worldwide, Chiesi employs over 7,000 people. The group’s main research and development centre is located at its headquarters in Parma, and it collaborates with six other major R&D hubs in France, the US, Canada, China, the UK, and Sweden.
Improving care for respiratory diseases
Chiesi is dedicated to enhancing the quality of life for individuals with respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Both conditions involve reduced respiratory flow, though they have different underlying causes.
They have developed the Modulite® technology, enabling the creation of pressurised metered dose inhalers (pMDIs) that deliver extra-fine particles. Additionally, they have introduced the NEXThaler, a dry powder inhaler (DPI) that also provides extra-fine particle delivery, enhancing treatment effectiveness.
Rare diseases therapeutics
In February 2020, Chiesi introduced Chiesi Global Rare Diseases, a new division dedicated to researching, developing, and commercialising treatments and support services for rare and ultra-rare diseases.
Chiesi markets treatments for alpha-mannosidosis, Leber’s hereditary optic neuropathy, and nephropathic cystinosis in select markets outside the US. The company is also developing a pipeline of innovative therapies for lysosomal storage disorders (LSDs) and other rare diseases.
Speciality care innovation
Chiesi’s Care brand pillar encompasses a range of products and services designed to support both specialised medical care and consumer healthcare.
These include products for the care of premature infants, those administered by medical professionals to treat specific chronic conditions, and over-the-counter healthcare products available directly to consumers.
Commitment to sustainability and equality
As a Benefit Corporation in Italy and the US and as a Société à Mission in France, Chiesi has made a legally binding commitment to society, employees, the community, and the environment.
Sustainability is integral to Chiesi’s strategy and vision, and it is consistently monitored to maintain B Corp certification. The company aims to achieve net zero emissions by 2035 and earned Fair Pay Certification in 2022 by closing the gender pay gap.
